Teva Pharmaceutical Industries (NYSE:TEVA) updated its FY 2019
Pre-Market earnings guidance on Monday. The company provided EPS guidance of $2.30-2.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.38. The company issued revenue guidance of $$17.2-17.4 billion, compared to the consensus revenue estimate of $$17.18 billion.
Several research analysts have recently weighed in on TEVA shares. ValuEngine cut shares of Teva Pharmaceutical Industries from a strong-buy rating to a buy rating in a research report on Tuesday, December 3rd. Wells Fargo & Co decreased their target price on shares of Teva Pharmaceutical Industries from $17.00 to $8.00 and set a market perform rating on the stock in a research report on Monday, September 30th. UBS Group set a $8.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a hold rating in a research report on Friday, August 16th. Guggenheim initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Thursday, September 12th. They set a neutral rating on the stock. Finally, Gabelli upgraded shares of Teva Pharmaceutical Industries from a hold rating to a buy rating in a research note on Wednesday, October 16th. Five research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $10.64.
TEVA traded down $0.25 during trading on Tuesday, reaching $9.57. 6,578,309 shares of the company were exchanged, compared to its average volume of 19,349,124. The company has a current ratio of 0.89, a quick ratio of 0.56 and a debt-to-equity ratio of 1.62. The stock has a market cap of $10.83 billion, a P/E ratio of 3.42, a PEG ratio of 1.06 and a beta of 1.82. The firm has a 50 day moving average of $9.36 and a 200 day moving average of $8.32. Teva Pharmaceutical Industries has a 52 week low of $6.07 and a 52 week high of $20.21.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.56 earnings per share for the quarter, missing the consensus estimate of $0.58 by ($0.02). The business had revenue of $4.26 billion for the quarter, compared to analyst estimates of $4.25 billion. Teva Pharmaceutical Industries had a negative net margin of 22.88% and a positive return on equity of 15.41%. As a group, analysts forecast that Teva Pharmaceutical Industries will post 2.26 earnings per share for the current fiscal year.
In other Teva Pharmaceutical Industries news, VP Hafrun Fridriksdottir sold 4,310 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.49, for a total value of $45,211.90. Following the transaction, the vice president now directly owns 24,883 shares of the company’s stock, valued at approximately $261,022.67. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders sold 17,700 shares of company stock worth $99,877. Insiders own 0.49% of the company’s stock.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Article: What is net income?
Receive News & Ratings for Teva Pharmaceutical Industries Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com’s FREE daily email newsletter.